Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03120832 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
A Phase 1 study of Prostate Cancer, sponsored by Sensei Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT03120832 is a Phase 1 study of Prostate Cancer that has completed, run by Sensei Biotherapeutics. The registered enrollment target is 12 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03120832, a Phase 1 study of Prostate Cancer, has completed, sponsored by Sensei Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
Conditions Studied
Interventions
- BIOLOGICAL PAN-301-1
Study Locations (4)
Alabama
- Urology Centers of Alabama - Homewood
California
- Dr. James J. Elist - Beverly Hills
Nebraska
- GU Research Network/Urology Cancer Center - Omaha
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03120832
The ClinicalTrials.gov registry entry for NCT03120832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Sensei Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which PAN-301-1 is the first listed.
NCT03120832 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03120832 about?
NCT03120832 is a clinical study titled "Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients". This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
What is the current status of trial NCT03120832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-12. Estimated completion is 2018-12.
What conditions does trial NCT03120832 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03120832?
The interventions under investigation include: PAN-301-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03120832?
This trial is sponsored by Sensei Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03120832 being conducted?
This trial has 4 study locations across Alabama, California, Nebraska, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.